- Motley Fool•3 hours ago
Tesaro's cancer-fighting drug, niraparib, nabbed FDA approval roughly three months ahead of schedule.
- Zacks•3 hours ago
Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
- MarketWatch•3 hours ago
The company could be delaying price information because it’ll be higher than expected, according to some.
TSRO : Summary for TESARO, Inc. - Yahoo Finance
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||152.24 x 300|
|Ask||152.58 x 100|
|Day's Range||150.80 - 156.59|
|52 Week Range||36.68 - 192.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-18.69|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|